NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from SRY Labs? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
62%
Finnrick rating
#413 of 500 ranked vendors
90 of 136 classifiable tests passed
methodology · Purity focus
Finnrick analysis

SRY Labs' purity-focus record is split: Tirzepatide and Retatrutide test comparatively strong, while Tesamorelin and TB-500 carry repeated purity, identity, or fill misses. Recent data are broad and current, but batch IDs are uneven and weaker peptides show volatile results rather than a clear recovery.

methodology →
vendor intelligence report
Vendor Intelligence Report: SRY Labs

Corporate records lead to a real Shanghai Senria entity, but the live SRY storefront’s seller and UBO do not resolve from the legal notice, domains or wallet trail. DNS, mirror domains and checkout code expose a rotating web cluster and no-KYC payment path.

38 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.34
92%
36
2
Retatrutide
$0.83
88%
35
3
Ipamorelin
$0.70
74%
4
4
GHK-Cu
-
67%
9
5
Semaglutide
$0.55
64%
4
6
PT-141
$0.60
59%
2
7
Cagrilintide
$1.20
49%
8
8
BPC-157
$0.50
48%
8
10
TB-500
$1.15
39%
10
11
Tesamorelin
-
35%
12
12
CJC-1295
$2.60
33%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%25 Nov 2025: 55%25 Nov 2025: 55%18 Dec 2025: 55%15 Jan 2026: 55%15 Jan 2026: 55%29 Jan 2026: 55%30 Jan 2026: 55%2 Feb 2026: 55%2 Feb 2026: 55%2 Feb 2026: 55%15 Feb 2026: 55%15 Feb 2026: 55%20 Feb 2026: 55%20 Feb 2026: 55%20 Feb 2026: 56%2 Mar 2026: 56%2 Mar 2026: 56%2 Mar 2026: 56%2 Mar 2026: 56%6 Mar 2026: 57%13 Mar 2026: 57%19 Mar 2026: 57%25 Mar 2026: 57%25 Mar 2026: 57%23 Apr 2026: 58%6 May 2026: 58%8 May 2026: 58%8 Jun 2026: 58%20 Jul 2026: 58%15 Sep 2026: 58%15 Sep 2026: 59%15 Sep 2026: 60%15 Sep 2026: 60%24 Sep 2026: 60%1 Oct 2026: 60%5 Oct 2026: 60%20 Oct 2026: 60%20 Oct 2026: 60%20 Oct 2026: 60%20 Oct 2026: 60%17 Nov 2026: current 62%55%57%62%Nov 25Nov 26
Peptide testing

Ordered peptides from SRY Labs? Mail in a sample (US only) and let us test it.

Test my supply
SRY Labs test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
20 Oct 2026
Pass
GHK-Cu
lab nameView COA
20 Oct 2026
Pass
TB-500 (Thymosin Beta-4)
lab nameView COA
20 Oct 2026
Pass
Retatrutide
lab nameView COA
20 Oct 2026
Pass
Retatrutide
lab nameView COA
5 Oct 2026
Fail
Retatrutide
lab nameView COA
1 Oct 2026
Fail
GHK-Cu
lab nameView COA
24 Sep 2026
Pass
Retatrutide
lab nameView COA
15 Sep 2026
Fail
TB-500
lab nameView COA
15 Sep 2026
Pass
Ipamorelin
lab nameView COA
15 Sep 2026
Pass
BPC-157
lab nameView COA
1-10 of 136

About SRY Labs test results from Finnrick

SRY Labs is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 136 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible SRY Labs peptides in this dataset are Tirzepatide (36 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 136 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from SRY Labs? Mail in a sample (US only) and let us test it.

Test my supply